A contraindication is a specific medical condition or circumstance under which a drug should not be used at all, based on documented risk. Understanding the contraindications for GLP-1 drugs is a concrete example of how this kind of safety information gets established and applied.
The Primary Contraindication
Both semaglutide and tirzepatide are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), directly tied to the thyroid C-cell tumor findings observed in rodent studies discussed in this site's boxed warning article. This is treated as an absolute contraindication, not a relative caution.
Additional Cautions Around Pregnancy
GLP-1 drugs are generally not recommended during pregnancy, based on animal reproduction studies showing potential fetal risk, and prescribing information typically recommends discontinuing use before a planned pregnancy, given the drugs' extended half-life. This is covered in more detail in this site's dedicated article on peptides and pregnancy.
Caution With Certain Digestive Conditions
Because these drugs slow gastric emptying as part of their core mechanism, they carry specific caution, though not always an absolute contraindication, for patients with severe gastrointestinal disease, including severe gastroparesis, where further slowing digestion could worsen an existing condition.
Allergy History
As with any injectable drug, a known hypersensitivity or allergic reaction to the specific drug or its formulation components is a contraindication, and patients with a history of severe allergic reactions to similar drugs should discuss this directly with their prescriber before starting.
Why This List Is Relatively Short and Specific
Compared to some medications, the contraindication list for GLP-1 drugs is fairly focused, a reflection of the extensive trial and post-market data available to define these risks precisely rather than broadly. That specificity is itself a product of rigorous study, exactly the kind of safety characterization that's largely absent for unapproved peptides.
The Bottom Line
Contraindications exist because trial and post-market data identified real, specific risk in defined populations. A prescriber reviewing personal and family medical history before starting a GLP-1 medication is applying exactly this kind of established, evidence-based safety screening, which is worth taking seriously rather than skipping through a rushed telehealth intake.
Relative vs. Absolute Contraindications
It's worth distinguishing between absolute contraindications, like the MTC/MEN2 history discussed above, where the drug should not be used under any circumstances, and relative contraindications or cautions, situations where a physician weighs the specific risk against the specific benefit for that individual patient rather than avoiding the drug automatically. Severe gastrointestinal disease generally falls into this more nuanced, individualized category rather than being an absolute bar to use.